Related Experiment Video
Updated: Jul 2, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma
1Department of Hematology, Hospital of the Justus-Liebig-University of Giessen, Giessen, Germany. Mathias.Rummel@innere.med.uni-giessen.de
Seminars in Hematology
|September 2, 2008
Summary
Bendamustine plus rituximab shows high efficacy in treating relapsed indolent lymphoma. This combination therapy offers a promising alternative with excellent response rates and manageable toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bendamustine is a bifunctional chemotherapeutic agent with alkylator and purine analog properties.
- In vitro studies demonstrate synergistic effects between bendamustine and rituximab against leukemia and lymphoma cell lines.
Purpose of the Study:
- To evaluate the efficacy and safety of bendamustine in combination with rituximab for indolent lymphoma.
- To compare bendamustine plus rituximab with a standard chemotherapy regimen.
Main Methods:
- Clinical trials were conducted in patients with relapsed and refractory indolent lymphoma.
- A phase III randomized trial compared bendamustine plus rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab.
Main Results:
- Bendamustine plus rituximab demonstrated high response rates in rituximab-naive, pretreated, and refractory patients.
- The combination therapy exhibited favorable toxicity profiles.
- Interim results suggest bendamustine plus rituximab may be a viable alternative to CHOP plus rituximab.
Conclusions:
- Bendamustine, both as monotherapy and in combination with rituximab, is effective for indolent lymphoma.
- The bendamustine-rituximab regimen presents a potentially superior treatment option compared to standard CHOP-rituximab.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...